Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986172 · 1 trial · 1 indication
QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave
| Arm | Type | Description |
|---|---|---|
| Part A: SAD | EXPERIMENTAL | SAD = Single Ascending Dose |
| Part B: MAD | EXPERIMENTAL | MAD = Multiple Ascending Dose |
| Part C: JMAD | EXPERIMENTAL | JMAD= Japanese Multiple Ascending Dose |
| Part D: FE/BA | EXPERIMENTAL | FE/BA = Food Effect/Relative Bioavailability |
| Name | Type | Description |
|---|---|---|
| BMS-986172 | DRUG | Specified dose on specified days |
| Placebo | OTHER | Specified dose on specified days |
Inclusion Criteria: * Healthy participants as determined by no clinically significant deviation from normal in medical history, physical examination, vital signs, ECG, and clinical laboratory results as determined by the investigator or designee. * Participants in Part C must be first-generation Ja...
BMS-986172 is an investigational small molecule being studied in healthy participants. It is being evaluated for safety, tolerability, and drug levels, including the effects of food on its absorption. It is not approved for any condition and is in Phase 1 clinical development.
BMS-986172 is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company is conducting a Phase 1 study to assess the drug's safety, tolerability, and pharmacokinetics in healthy and obese participants.
BMS-986172 is in Phase 1 clinical development. The only trial listed for this drug is a Phase 1 study that has been completed. The drug is investigational and has not been approved by regulatory authorities.
BMS-986172 has one completed Phase 1 clinical trial, identified as NCT04926051. This study assessed the safety, tolerability, and drug levels of BMS-986172 in healthy and obese participants, including the effects of food on absorption. The trial was conducted in the United States with 40 participants.
BMS-986172 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial focused on safety, tolerability, and drug levels in healthy participants, and the drug has not yet progressed to later-stage trials or regulatory approval.